Selective and Sustained Delivery of Basic Fibroblast Growth Factor (bFGF) for Treatment of Peripheral Arterial Disease: Results of a Phase I Trial

European Journal of Vascular and Endovascular Surgery

Volumn 38, Issue 1, 2009, Pages 71-75

  Hashimoto, T ^a   Koyama, H ^a,b   Miyata, T ^a   Hosaka, A ^a   Tabata, Y ^c   Takato, T ^b   Nagawa, H ^a  

^a University of Tokyo   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Basic fibroblast growth factor; Critical ischaemia; Intermittent claudication; Microsphere; Peripheral arterial disease; Therapeutic angiogenesis

Indexed keywords

ACIDIC GELATINE HYDROGEL MICROSPHERE; BASIC FIBROBLAST GROWTH FACTOR; MICROSPHERE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BUERGER DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; MALE; OBSERVATIONAL STUDY; PERFUSION PRESSURE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REST; SKIN PERFUSION PRESSURE; SUSPENSION; SYMPTOM; TRANSCUTANEOUS CARBON DIOXIDE MONITORING; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ARTERIOSCLEROSIS OBLITERANS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRA-ARTERIAL; INTERMITTENT CLAUDICATION; MALE; MICROSPHERES; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; THROMBOANGIITIS OBLITERANS; TREATMENT OUTCOME;

EID: 67349109870     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.02.005     Document Type: Article

References (15)

1. Scholz D., Ziegelhoeffer T., Helisch A., Wagner S., Friedrich C., Podzuweit T., et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 34 7 (2002 Jul) 775-787
2. Helisch A., and Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 10 1 (2003 Jan) 83-97
3. Heil M., Ziegelhoeffer T., Pipp F., Kostin S., Martin S., Clauss M., et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283 6 (2002 Dec) H2411-H2419
4. Ziegelhoeffer T., Fernandez B., Kostin S., Heil M., Voswinckel R., Helisch A., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94 2 (2004 Feb 6) 230-238
5. van Royen N., Piek J.J., Buschmann I., Hoefer I., Voskuil M., and Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 49 3 (2001 Feb 16) 543-553
6. Wahlberg E. Angiogenesis and arteriogenesis in limb ischaemia. J Vasc Surg 38 1 (2003 Jul) 198-203
7. Deindl E., Hoefer I.E., Fernandez B., Barancik M., Heil M., Strniskova M., et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ Res 92 5 (2003 Mar 21) 561-568
8. Fujii T., Yonemitsu Y., Onimaru M., Tanii M., Nakano T., Egashira K., et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol 26 11 (2006 Nov) 2483-2489
9. Unger E.F., Banai S., Shou M., Lazarous D.F., Jaklitsch M.T., Scheinowitz M., et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 266 4 Pt 2 (1994 Apr) H1588-H1595
10. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 9323 (2002 Jun 15) 2053-2058
11. Lazarous D.F., Unger E.F., Epstein S.E., Stine A., Arevalo J.L., Chew E.Y., et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36 4 (2000 Oct) 1239-1244
12. Hosaka A., Koyama H., Kushibiki T., Tabata Y., Nishiyama N., Miyata T., et al. Gelatin hydrogel microspheres enable selective delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110 21 (2004 Nov 23) 3322-3328
13. Tabata Y., Hijikata S., Muniruzzaman M., and Ikada Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed 10 1 (1999) 79-94
14. Tabata Y., and Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 20 22 (1999 Nov) 2169-2175
15. Mazue G., Bertolero F., Jacob C., Sarmientos P., and Roncucci R. Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann N Y Acad Sci 638 (1991) 329-340